학술논문
Cost‐effectiveness of the subcutaneous house dust mite allergen immunotherapy plus pharmacotherapy for allergic asthma: A mathematical model.
Document Type
Article
Author
Source
Subject
*HOUSE dust mites
*ASTHMA
*COST effectiveness
*ALLERGENS
*MEDICAL personnel
*WHEEZE
*
*
*
*
*
Language
ISSN
0105-4538
Abstract
Previous research suggests that allergen immunotherapy (AIT) may be cost-effective for the treatment of patients with allergic asthma (AA).1,2 However, most evidence is based on randomized controlled trials, and the use of policy-relevant outcomes like exacerbations and medication step down is lacking. Considering AR as a comorbid condition in this population resulted in an ICER 27.5% lower compared to adult patients with AA alone. These clinical gains are projected to come at a higher total cost of the SCIT+ICS intervention resulting from the additional cost of SCIT administration in the first three years of the model (76.6% of total SCIT+ÍCS costs). [Extracted from the article]